# Dose-Escalation, Safety, Pharmacokinetics Study of Cabazitaxel With Gemcitabine In Patients With Solid Tumor

> **NCT01001221** · PHASE1,PHASE2 · TERMINATED · sponsor: **Sanofi** · enrollment: 19 (actual)

## Conditions studied

- Neoplasms, Malignant

## Interventions

- **DRUG:** cabazitaxel
- **DRUG:** gemcitabine

## Key facts

- **NCT ID:** NCT01001221
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-11
- **Primary completion:** 2011-10
- **Final completion:** 2011-10
- **Target enrollment:** 19 (ACTUAL)
- **Why stopped:** Maximum tolerated dose not able to be determined
- **Last updated:** 2013-09-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01001221

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01001221, "Dose-Escalation, Safety, Pharmacokinetics Study of Cabazitaxel With Gemcitabine In Patients With Solid Tumor". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01001221. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*